BioSpace News Archive

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed.

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the for the first quarter of 2023.

Abcam plc, a global leader in the supply of life science research tools, notes that its founder and former director Dr. Jonathan Milner has indicated he will take steps to call an extraordinary general meeting of the Company’s shareholders to elect himself to the Company’s Board of Directors as Executive Chairman.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock.

Fluent BioSciences in collaboration with GenomeWeb and the Liddelow Lab, will host a webinar to explore the use of PIPseq, an innovative single-cell RNA sequencing technology.

Ainos, Inc. announced the appointment of Ms. Meng-Lin Sung to the position of Chief Financial Officer, effective May 17, 2023.

Cabaletta Bio, Inc. announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $12.00 per share.

Synthego Corp. has announced a victory in its dispute with Agilent Technologies, Inc., regarding two of Agilent’s patents which have been invalidated by a ruling of the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.

Prime Medicine, Inc. announced the presentation of new preclinical data that further demonstrated the potential of Prime Editing to correct the causative mutation of chronic granulomatous disease and preclinical data that showcased the potential application of the Prime Editing Assisted Site-Specific Integrase Gene Editing platform to generate multiplex-edited CAR-T cells for the treatment of certain cancers and immune diseases.

Alvotech announced its participation in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023.